Basel, Switzerland, April 27, 2022
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with bacterial and fungal infections and cancer, today announced that it has entered into a licensing agreement with US-based Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel, first-in-class broad-spectrum antifungals with activity against difficult-to-treat mold infections.
Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: “This agreement demonstrates our commitment to implementing our new business strategy, with a future focus on anti-infectives. The profile and broad antifungal activity of the lead compound shown in preclinical studies are very promising. We will now focus on completing the preclinical profiling of the lead compound, which will be instrumental in the development strategy and positioning of this new class of antifungal agents.
Under the terms of the agreement, Basilea is granted an exclusive worldwide license for the FCCDC’s antifungal program. FCCDC receives an undisclosed upfront payment and is eligible for further payments, achievement of pre-defined development, regulatory and commercial milestones, and tiered royalties on net sales. This transaction has no impact on Basilea’s financial forecast for 2022, provided on February 15, 2022.
About the FCCDC
Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA, at the Pennsylvania Biotechnology Center (PABC) and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI). The FCCDC conducts early-stage drug discovery research, including target validation, medicinal chemistry, in vitro pharmacology, and ADME characterization. The goal of the FCCDC is to transform innovative biomedical research technologies into full-fledged development programs for eventual evaluation in human clinical trials and commercialization. The FCCDC’s antifungal program work was supported by the U.S. Office of the Assistant Secretary of Defense for Health Affairs through the Peer-Reviewed Medical Research Program under award number W81XWH-18-1-0638 .
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and based in Switzerland. We are committed to discovering, developing and commercializing innovative medicines to meet the medical needs of patients with bacterial and fungal infections and cancer. We successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have several preclinical anti-infectives and cancer assets in our pipeline. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “plan”, “project”, “may”, “could”, “might”, “will”. or similar expressions relating to Basilea Pharmaceutica Ltd. and its activities, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. are materially different from any future results, performance or achievements expressed or implied by such statements. – look at the statements. Basilea Pharmaceutica Ltd. provides this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For more information, please contact:
This press release can be downloaded from www.basilea.com.